glp 1 agonist and depression GLP-1s: Are We Ignoring the Psychiatric Risks? Most GLP-1 Medications Correlated with

Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes

Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes

Bioengineered nanomedicines targeting the intestinal fc receptor achieve the improved glucoregulatory effect of semaglutide in a type 2 diabetic mice model

3) exenatide OR lixisenatide OR liraglutide OR semaglutide OR albiglutide OR dulaglutide OR efpeglenatide

1 giugno 2021 [citato 5 giugno 2024];38(6):282139